Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $322

Benzinga · 2d ago
Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $283 to $322.